Senseonics Holdings, Inc. (NYSEAMERICAN:SENS) saw its stock soar by 5.53% in Wednesday's intraday session, as investors rallied behind the company's promising growth prospects fueled by the success of its Eversense 365 continuous glucose monitoring (CGM) system.
The implantable CGM system, designed for diabetes patients, has gained significant traction among users due to its unique ability to last a full year without frequent sensor replacements. This groundbreaking feature has positioned the Eversense 365 as a game-changer in the CGM market, attracting new patients and driving revenue growth for Senseonics.
Preliminary results for 2024 indicate total revenue of around $22.5 million, and the company expects positive revenue trends to continue in 2025 as the Eversense 365 system gains further adoption. With the FDA approval for the system already secured, Senseonics is poised to capitalize on the growing demand for long-term CGM solutions among diabetes patients.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。